Details for Patent: 8,778,373

Which drugs does patent 8,778,373 protect, and when does it expire?

Patent 8,778,373 protects RAYALDEE and is included in one NDA.

This patent has fifty-two patent family members in fifteen countries.

Summary for Patent: 8,778,373

Title:	Methods for controlled release oral dosage of a vitamin D compound
Abstract:	A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.
Inventor(s):	Bishop; Charles W. (Mount Horeb, WI), Tabash; Samir P. (Whitby, CA), Agudoawu; Sammy Asiamah (Mississauga, CA), White; Jay A. (Newmarket, CA), Crawford; Keith H. (Highlands Ranch, CO), Messner; Eric J. (Lake Forest, IL), Petkovich; P. Martin (Kingston, CA)
Assignee:	Opko IP Holdings II, Inc. (Grand Cayman, KY) Opko Renal, LLC (Miami, FL)
Application Number:	13/746,982
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 8,778,373

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Eirgen	RAYALDEE	calcifediol	CAPSULE, EXTENDED RELEASE;ORAL	208010-001	Jun 17, 2016		RX	Yes	Yes						ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE

International Family Members for US Patent 8,778,373

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2683997
Canada	2943032
China	101668517
China	104523707